Dear Gattex leadership!

Discussion in 'Shire' started by anonymous, Sep 16, 2017 at 4:57 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Then apparently they are not capable of running any business. Rare disease, biotec or pharma. Fantastic leadership at this company
     

  2. anonymous

    anonymous Guest

    My goal was 3 and I hit 1. Got paid $0 for my bonus. This is rare disease and we need to get paid out on every ship. If not pay us more larger of a base salary. Current bonus plan is horrendous leadership!
     
  3. anonymous

    anonymous Guest

    Zero? That's crazy. You need to get out of there.
     
  4. anonymous

    anonymous Guest

    Gattex sales were way up last quarter. Did management take away bonuses or was the payout appropriate for speciality sales?
     
  5. anonymous

    anonymous Guest

    Do a better job of selling and you will be rewarded appropriately. We can't dole out bonus $s to losers! You are in sales so PERFORM!!
     
  6. anonymous

    anonymous Guest

    Q: You know what Shire calls reps who don’t perform don’t ya?

    A: Regional Business Directors
     
  7. anonymous

    anonymous Guest

    correction, Gattex revenue was way up last quarter
     
  8. anonymous

    anonymous Guest

    IC has to be changed for those reps that actually sell something. This is not right.
    Come on, this is an easy one. You should be able to see the issues and correct before end of year.

    Leadership has to do something or look ( ) .
     
  9. anonymous

    anonymous Guest

    [QUOTE="anonymous, post: 5952834


    " IC has to be changed for those reps that actually sell something. This is not right.
    Come on, this is an easy one. You should be able to see the issues and correct before end of year.

    Leadership has to do something or look ( )


    YES !!!! Real Bonus would be good thing.
     
  10. anonymous

    anonymous Guest

    Increase in revenue due to continuing price increases. $300,000/year at launch and now well over $400,000/year without any data other than the original Phase 3 study.
     
  11. anonymous

    anonymous Guest


    ( The medication is not an issue.) Don't be stupid .


    We need to pay for performance. That is an issue. Bonus on sales and stop the BS.
     
  12. anonymous

    anonymous Guest

    Leadership needs a downsizing. Half these RBD’s are clueless. They are overpaid and contribute ZERO to the bottom line. Get rid of the lowest performing RBD’s. Flemming will love the cost savings. That would be a welcome Christmas gift to the long suffering shareholders. Cheers!
     
  13. anonymous

    anonymous Guest

     
  14. anonymous

    anonymous Guest

    First it was Lialda of year to year sales growth and money made for Shire. Now it’s Gattex with record earnings this year and ships. Yet, we don’t get paid on EVERY ship. That’s bullshit! Pay your reps on every ship. If a rep gets 1 ship on on a goal of 3 the rep should be PAID! We have such sorry ass leaders leading this business unit. KW and DZ are two leaders that suck! They can not inspire a sales team when on a conference call or on stage, they don’t have the knowledge of rare disease and they have no strategy beyond “ we need more start forms.” No shit!
     
  15. anonymous

    anonymous Guest

    Um if the goal is 3 and you got 1 then you missed your goal and should not be paid. Pretty simple.
    Honestly 90% of the reps here are no better than PC reps anyway and have no clue how to truly work a rare disease territory. Thus why companies launching rare disease drugs aren’t going near this sales force.
     
  16. anonymous

    anonymous Guest

    Your not getting the point here Mr. Rare Disease expert. First, why are you trolling this site. Miss Shire already? Second, selling a rare disease is not rocket science. It just comes to persistence and access. So, take your expert rare disease opinion where the sun don’t shine. If a rep finds a patients and it ships. Rep should get paid.
     
  17. anonymous

    anonymous Guest

    If it’s not rocket science than you idiots shouldn’t have a problem hitting your goal
     
  18. anonymous

    anonymous Guest

    Thats why it’s called rare disease dumb ass! It is not rocket science, yes! but you got to find patients which correlates to persistence and access.
     
  19. anonymous

    anonymous Guest

    Gattex is a shit drug. Anyone who "responds" does so in the first two months. The nonresponders (85% of patients) should discontinue at month 3. This is a typical biotech bullshit drug.
     
  20. anonymous

    anonymous Guest

    Since SBS has a slow growth in new patients and most of the original SBS patients have started and failed Gattex, it seems that there is are not too many more patients to target. Unless you expand the definition of PS dependent or just sale off-label.